Sage Mountain Advisors LLC Purchases 345 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sage Mountain Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,717 shares of the biopharmaceutical company’s stock after buying an additional 345 shares during the period. Sage Mountain Advisors LLC’s holdings in Gilead Sciences were worth $301,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. Monument Capital Management increased its stake in Gilead Sciences by 11.4% in the fourth quarter. Monument Capital Management now owns 10,957 shares of the biopharmaceutical company’s stock valued at $888,000 after purchasing an additional 1,120 shares in the last quarter. Significant Wealth Partners LLC bought a new stake in Gilead Sciences in the 4th quarter valued at about $1,353,000. Telemus Capital LLC raised its stake in Gilead Sciences by 10.0% during the 4th quarter. Telemus Capital LLC now owns 19,589 shares of the biopharmaceutical company’s stock worth $1,587,000 after buying an additional 1,788 shares during the period. MCF Advisors LLC boosted its holdings in Gilead Sciences by 8.7% in the fourth quarter. MCF Advisors LLC now owns 7,196 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 573 shares in the last quarter. Finally, Capital Investment Advisory Services LLC grew its stake in Gilead Sciences by 6.6% in the fourth quarter. Capital Investment Advisory Services LLC now owns 13,308 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 820 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Barclays reduced their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Mizuho lowered their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Oppenheimer reiterated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday. Finally, Wells Fargo & Company lowered their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $84.71.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $66.93 on Tuesday. The company has a market capitalization of $83.33 billion, a PE ratio of 14.88, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86. The company has a 50-day simple moving average of $71.81 and a 200 day simple moving average of $76.51.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the firm posted $1.67 EPS. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, research analysts predict that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.